Biotėkmė - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 40,720 | 50,527 | 45,467 | 39,626 | 92,148 | 38,719 | 19,683 | 31,662 |
| Profit before tax | 23,409 | 24,055 | 18,529 | 8,741 | 54,898 | 7,181 | -4,564 | 14,782 |
| Net profit | 23,409 | 22,851 | 17,611 | 7,882 | 52,135 | 6,808 | -4,564 | 14,156 |
| Equity | 39,925 | 62,776 | 80,386 | 88,268 | 140,403 | 147,211 | 142,747 | 157,703 |
| Liabilities | - | - | - | - | 8,016 | 6,815 | 5,031 | 4,307 |
| Non-current assets | 0 | 2,663 | 3,413 | 1,617 | 985 | 527 | 244 | 127 |
| Current assets | 43,157 | 66,966 | 84,522 | 91,069 | 147,434 | 153,499 | 147,534 | 161,883 |
| Total assets | 43,157 | 69,629 | 87,935 | 92,686 | 148,419 | 154,026 | 147,778 | 162,010 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 5,905 | 2,925 | 2,403 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +65.6% | +24.1% | -10.0% | -12.8% | +132.5% | -58.0% | -49.2% | +60.9% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 54.2% | 32.8% | 20.0% | 8.5% | 35.1% | 4.4% | -3.1% | 8.7% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 58.6% | 36.4% | 21.9% | 8.9% | 37.1% | 4.6% | -3.2% | 9.0% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 57.5% | 45.2% | 38.7% | 19.9% | 56.6% | 17.6% | -23.2% | 44.7% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 57.5% | 47.6% | 40.8% | 22.1% | 59.6% | 18.5% | -23.2% | 46.7% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | - | - | - | - | 0.1 | 0.0 | 0.0 | 0.0 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | - | - | - | - | 92,148 | 38,719 | - | - |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Biotėkmė - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2023-05-02 | 2023-08-31 | 58.63 |
| 2023-04-03 | 2023-04-30 | 58.63 |
| 2022-08-02 | 2022-08-31 | 173.81 |
| 2022-07-01 | 2022-07-31 | 50.95 |
Biotėkmė - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-07-01 | 2026-07-07 | 0.51 |
| 2026-02-28 | 2026-03-22 | 0.21 |
| 2025-10-02 | 2025-10-24 | 0.21 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Biotekme, MB (code 304066303) is a Lithuanian small partnership operating in landscape service activities. In 2025, the latest financial year, the company generated €31.7K in revenue and €14.2K in net profit, giving a profit margin of 44.7%. Revenue increased by 60.9% year on year from €19.7K in 2024, when the company posted a €4.6K loss, but it remained 18.2% below the 2023 level of €38.7K. The three-year trajectory therefore shows a decline in 2024 followed by a strong recovery in 2025. The balance sheet strengthened further in 2025, with total assets of €162.0K, equity of €157.7K and liabilities of €4.3K. The equity ratio was 97.3%, and debt to equity was very low at 0.03. ROE reached 9.0% and ROA 8.7%, while asset turnover stood at 0.20x, indicating that revenue was modest relative to the asset base.